DexCom, Inc. (NASDAQ:DXCM) Stake Raised by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,911 shares of the medical device company’s stock after acquiring an additional 17,650 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in DexCom were worth $11,768,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in DXCM. Versant Capital Management Inc acquired a new position in DexCom in the 4th quarter worth about $25,000. Riverview Trust Co grew its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter valued at approximately $38,000. MassMutual Private Wealth & Trust FSB increased its holdings in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after buying an additional 265 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC bought a new position in DexCom during the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 0.5 %

DexCom stock opened at $88.32 on Friday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a market cap of $34.50 billion, a price-to-earnings ratio of 52.89, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. The business has a 50 day moving average price of $81.35 and a two-hundred day moving average price of $75.69. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Activity at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,342 shares of company stock worth $3,628,069. 0.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DXCM shares. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price target for the stock from $85.00 to $115.00 in a research note on Monday. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer reduced their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Citigroup increased their price objective on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.